Durandy A, Schiff C, Bonnefoy J Y, Forveille M, Rousset F, Mazzei G, Milili M, Fischer A
INSERM U 132, Hôpital des Enfants-Malades, Paris, France.
Eur J Immunol. 1993 Sep;23(9):2294-9. doi: 10.1002/eji.1830230936.
We studied the ability of B lymphocytes from patients with X-linked hyper IgM syndrome (HIGM1) to be activated via the CD40 membrane receptor. HIGM1 is caused by a CD40 ligand gene mutation, leading to defective expression on the membrane of activated T lymphocytes. We found that triggering of B cells by an anti-CD40 monoclonal antibody or the soluble CD40 ligand plus interleukin (IL)-4 or IL-10 led to B cell proliferation and/or differentiation towards IgG, IgA and IgE secretion. This was reflected by transcription of C gamma, alpha and epsilon membrane isotype expression and IgG, IgA and IgE production. These results confirm the integrity of B cells in patients with the HIGM1 immunodeficiency and open up new therapeutic possibilities.
我们研究了患有X连锁高IgM综合征(HIGM1)患者的B淋巴细胞通过CD40膜受体被激活的能力。HIGM1是由CD40配体基因突变引起的,导致活化T淋巴细胞膜上的表达缺陷。我们发现,用抗CD40单克隆抗体或可溶性CD40配体加白细胞介素(IL)-4或IL-10触发B细胞会导致B细胞增殖和/或分化为分泌IgG、IgA和IgE。这通过Cγ、α和ε膜同种型表达的转录以及IgG、IgA和IgE的产生得以体现。这些结果证实了HIGM1免疫缺陷患者B细胞的完整性,并开辟了新的治疗可能性。